RxDoctor Payments Data

Suganthi Ravindran, MD

Internal Medicine · Ronkonkoma, NYNPI 1578659819

Payments from drug & device makers

$459in general payments, 2019–2025

Across 22 payments — averaging $20.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$151
  • Pfizer$82
  • AbbVie$78
  • Lilly USA, LLC$46
  • Esperion Therapeutics, Inc.$32
  • Boehringer Ingelheim$30
  • plus $39 from 2 others

What the payments were for

  • Food & beverage$42492%
  • Education$358%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$459 in reported general payments places this provider in the 60th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$198,105
Medicare patients
267
Services billed
2,067

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin76$81,991
JanuviaSitagliptin Phosphate38$43,486
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$38,198
Janumet XrSitagliptin Phos/Metformin Hcl30$34,049
EliquisApixaban19$26,833
OzempicSemaglutide24$25,996
Breo ElliptaFluticasone/Vilanterol14$8,785
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$3,240
Atorvastatin Calcium448$2,982
Azelastine Hcl90$2,834
Albuterol Sulfate HfaAlbuterol Sulfate63$2,763
Metoprolol Succinate213$2,383
Venlafaxine Hcl ErVenlafaxine Hcl86$2,264
Ezetimibe101$2,153
Levothyroxine Sodium186$1,814

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$30$81,99176 claims
PfizerEliquis$82$26,83319 claims
AbbVieSynthroid$78$1,06022 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Ronkonkoma

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →